Gimoti denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Imposes Quantity Limits on Gimoti

Quantity limits (QL) are a formulary management tool. For Gimoti (metoclopramide nasal spray), BCBS may restrict the number of doses dispensed per fill or per coverage period. These limits are typically set based on the FDA-approved dosing regimen described in the prescribing information, but the plan's limit may be more restrictive than what your prescriber has determined is appropriate for your individual case. A quantity-limit denial means the pharmacy received a prescription that exceeded the plan's pre-set ceiling.

## Why This Denial Is Appealable

If your prescriber has determined that you require a quantity beyond the plan's standard limit, that clinical judgment can be the basis of a quantity-limit exception. The appeal must show that the prescribed quantity is consistent with the FDA-approved prescribing information and that your specific clinical circumstances — symptom severity, frequency of gastroparesis episodes, or other documented factors — support the higher quantity. Insurers are required to evaluate these exceptions on an individual basis.

## Your Federal Appeal Rights

• Quantity-limit exception request: Ask your prescriber to submit a quantity-limit exception directly to BCBS's pharmacy benefit team — this is often faster than a formal appeal and can proceed in parallel.
• Internal appeal (ERISA §503 / ACA §2719): If the exception is denied, escalate to a written internal appeal. The denial letter must state the deadline and process.
• External review (ACA §2719): After internal appeals are exhausted, you may request independent external review. The reviewer will assess whether the clinical documentation supports the prescribed quantity. Decisions arrive within 45 days standard, or 72 hours on expedited review.

## Documentation to Gather

• Prescriber's clinical justification: A letter explaining why the prescribed quantity is medically necessary — for example, the frequency of breakthrough gastroparesis episodes documented in the chart, and why that frequency aligns with the FDA-approved use of the drug.
• FDA prescribing information: The current approved label establishes the permissible dosing range. Your prescribed quantity should be reconcilable with the label; if it is, include the label as an exhibit.
• Chart documentation of symptom frequency: Clinical notes, care-coordination records, or patient-reported outcome documentation establishing how often the patient requires the medication.
• Prior fill history: Pharmacy records showing whether the patient has used Gimoti before, at what quantity, and with what clinical benefit.

## Criteria-Mapping Structure

Obtain the specific quantity limit BCBS applies to Gimoti and the exception criteria from the plan's published coverage policy or the denial letter. Then build:

| Quantity-Limit Exception Criterion | Supporting Evidence | |---|---| | Prescribed quantity consistent with FDA label | [Cite FDA prescribing information section on dosing] | | Clinical need for higher quantity documented | [Chart note dates and symptom-frequency documentation] | | Prescriber attestation | [Signed prescriber letter with clinical rationale] |

Ensure that the prescribed quantity your prescriber is requesting does not exceed what is described in the FDA-approved prescribing information — if it does, the letter should explain that specific clinical justification clearly, as exceeding labeled quantities is a higher bar to clear.